Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:tegafur
gptkb:gimeracil gptkb:oteracil |
| gptkbp:approvedBy |
gptkb:European_Union
2011 |
| gptkbp:ATCCode |
L01BC53
|
| gptkbp:combines |
gptkb:cisplatin
|
| gptkbp:contraindication |
severe renal impairment
severe bone marrow suppression |
| gptkbp:developedBy |
gptkb:Taiho_Pharmaceutical
|
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teysuno
|
| gptkbp:indication |
advanced gastric cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
Nordic Group B.V.
|
| gptkbp:mechanismOfAction |
antineoplastic agent
inhibits DNA synthesis |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea fatigue neutropenia |
| gptkbp:usedFor |
gastric cancer
|
| gptkbp:bfsParent |
gptkb:Taiho_Pharmaceutical
gptkb:Taiho_Pharmaceutical_Co.,_Ltd. |
| gptkbp:bfsLayer |
7
|